(Q37571975)

21 August 2017

1 reference

title

Developing intrabodies for the therapeutic suppression of neurodegenerative pathology (English)

1 reference

21 August 2017

0 references

1 reference

Anne Messer

1

1 reference

21 August 2017

Sandra M Lynch

series ordinal

2

1 reference

21 August 2017

David C Butler

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1189-1197

1 reference

A new means of inducibly inactivating a cellular protein

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intrabody strategies for the treatment of human papillomavirus-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intracellular antibodies (intrabodies) and their therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intrabody applications in neurological disorders: progress and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intrabody and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Domain antibodies: proteins for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Yeast display of antibody fragments: a discovery and characterization platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Selection of antibodies for intracellular function using a two-hybrid in vivo system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Camelid immunoglobulins and nanobody technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A novel designed single domain antibody on 3-D structure of ricin A chain remarkably blocked ricin-induced cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

'Camelising' human antibody fragments: NMR studies on VH domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Inactivation of the mouse Huntington's disease gene homolog Hdh

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Huntingtin as an essential integrator of intracellular vesicular trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Huntington's disease: from pathology and genetics to potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Mouse models of Huntington's disease and methodological considerations for therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Huntingtin localization in brains of normal and Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Polyglutamine expansion of huntingtin impairs its nuclear export

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Protein misfolding inside cells: the case of huntingtin and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Emerging pathways in genetic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Biochemical aspects of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Kinase activity of mutant LRRK2 mediates neuronal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Detecting morphologically distinct oligomeric forms of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Direct binding of alpha-actinin enhances TRPP3 channel activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Autosomal dominant parkinsonism associated with variable synuclein and tau pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Development of antibody fragments for immunotherapy of prion diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

CNS delivery of vectored prion-specific single-chain antibodies delays disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903176387

10.1517/14712590903176387

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference